We previously identified osteopontin (OPN) as a promising marker for the early detection of hepatocellular carcinoma (HCC). In this study, we investigated the association between pre-diagnostic circulating OPN levels and HCC incidence in a large population-based cohort. A nested-case control study was conducted within the EPIC cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each case was matched to two controls and OPN levels were measured in baseline plasma samples. Viral hepatitis, liver function and alpha-fetoprotein (AFP) tests were also conducted. Conditional logistic regression models were used to calculate multivariable odds ratio (OR) and 95% confidence intervals (95%CI) for OPN levels in relation to HCC. Receiver operating characteristics curves were constructed to determine the discriminatory accuracy of OPN alone or in combination with other liver biomarkers in the prediction of HCC. OPN levels were positively associated with HCC risk (per 10% increment, OR multivariable =1.30; 95%CI:1.14-1.48). The association was stronger among cases diagnosed within two years of follow-up. Adding liver function tests to OPN improved the discriminatory performance for subjects who developed HCC (AUC=0.86). For cases diagnosed within two years, the combination of OPN and AFP was best able to predict HCC risk (AUC=0.88). The best predictive model for HCC in this low-risk population is OPN in combination with liver function tests. Within two years of diagnosis, the combination of OPN and AFP best predicted HCC development, suggesting that measuring OPN and AFP could identify high-risk groups independently of a liver disease diagnosis.
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Introduction
Liver cancer is the sixth most commonly diagnosed cancer and the second leading cause of cancer death worldwide (1) . Hepatocellular carcinoma (HCC), the most common type of liver cancer (2), is primarily associated with chronic hepatitis B and C virus (HBV/HCV) infections, heavy alcohol drinking, smoking, non-alcoholic steatohepatitis (NASH) and, in high incidence areas, dietary exposure to aflatoxin (3) (4) (5) . HCC incidence rates have increased over the past 20 years in Western Europe and the United States (2). The aging HCV infected population and the growing pandemic of diabetes and obesity causing NASH are thought to be largely responsible for the observed surge in HCC incidence. HCC is often diagnosed at a late stage and has poor prognosis due to limited treatment options. Because mainly small tumors are accessible to curative treatments and such tumors are asymptomatic, identification of high risk individuals that would benefit from surveillance and novel biomarkers for early detection of this highly lethal disease are urgently needed. For the last 40 years, α-fetoprotein (AFP) has been the only serum marker routinely used by clinicians together with ultrasound for the detection and surveillance of HCC, despite its low sensitivity (ranging from 41 to 65%) for the detection of early-stage HCC (6, 7) .
We have previously identified osteopontin (OPN) as an early stage HCC biomarker with greater performance than AFP as well as complementary properties to AFP in discriminating HCC patients in a population already at high risk for HCC development (8, 9) . Furthermore, we showed that the performance of OPN remained intact a year prior to HCC diagnosis in this high risk group (8, 9) . The performance of OPN for the early detection of HCC was further validated in independent studies (10-12). OPN is an extracellular matrix protein that has been implicated in several carcinogenic and angiogenic processes, such as cell invasion, inflammation, tumor progression, and metastasis (13, 14) . High OPN levels have also been associated with reduced survival in patients with lung, prostate, breast or liver cancers (15, 16) .
The aim of this study was to investigate the behaviour of circulating OPN in periods preceding HCC diagnosis in the general population, taking advantage of the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, a large heterogeneous cohort of Europeans, with a nested case-control subset for which measurements of HBV/HCV infection status and liver function biomarkers were conducted. EPIC is a large prospective cohort of >520,000 participants from 10 Western European countries, designed to investigate the association between diet, lifestyle and environmental factors and the incidence of cancers and other chronic diseases (17, 18) .
In EPIC, it was reported that smoking contributed to more HCCs (47.6%) than chronic HBV (13.2%) and HCV (20.9%) infections. Heavy alcohol consumption (10.2%) and obesity (16.1%) also contributed to sizeable fractions of this disease burden. Over onethird of HCCs could not be accounted for by exposure to at least one of the documented risk factors (19) . In follow-up studies, associations with diet and vitamin D levels were reported (20, 21) . The present study is the first to evaluate a novel biomarker for early detection of HCC and its behaviour in relation to time to diagnosis in EPIC.
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Materials and methods

Study Population and Follow-up for Cancer Incidence
Detailed information on the study design, rationale and methods of the EPIC study, including assessment of diet and lifestyle factors, has been described previously (17, 18) . Briefly, between 1991 and 2000 more than 520,000 men and women aged 20-85 years were recruited in 23 centres throughout 10 European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the The design of the nested case-control study has been previously described (19) .
A total of 125 HCC cases with available blood samples at baseline were identified between participants' recruitment and 2006. For each case, two controls were selected by incidence density sampling from all cohort members alive and free of cancer (except non-melanoma skin cancer). The controls were matched by age at blood collection (±1 year), sex, study center, date (±2 months) and time of the day (±3 hours) at blood collection, and by fasting status (<3/3-6/>6 hours) at blood collection. 
Serum Biomarkers
Data for HBV and HCV seropositivity, for AFP and C-reactive protein (CRP) levels and for liver function tests, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), albumin and total bilirubin were available and measured as previously described (20) . In addition, the ratio of AST/ALT and BARD score were calculated and used as markers of liver fibrosis (22) . BARD score, a non-invasive scoring system used to predict fibrosis severity in patients with non-alcoholic fatty liver disease, was calculated as the sum of BMI >28 = 1 point, AST/ALT >0.8 = 2 points and diabetes = 1 point.
Plasma concentrations of OPN were measured using a commercial ELISA kit from R&D Systems (Minneapolis, MN) as previously described (8) . Briefly, 50 µl of diluted (1:100) plasma samples were added to the ELISA plates pre-coated with a capture OPN antibody.
Statistical Analysis
Relevant baseline lifestyle and socio-demographic characteristics were described among cancer cases and matched controls. To assess correlations between OPN and liver function tests and other relevant variables, spearman partial correlation coefficients adjusted for age at recruitment and sex were estimated in cases and controls.
Conditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for associations between OPN levels and HCC risk. For all analyses, both crude and multivariable models were run. Crude models were conditioned on the matching factors while multivariable models were additionally adjusted for the following relevant confounding factors: baseline alcohol intake at recruitment (g/d), pattern of lifetime alcohol intake (never drinker, former light drinker, former heavy drinker, light drinker, never heavy drinker, periodically heavy drinker, always heavy drinker, unknown), body mass index (BMI; kg/m 2 ), and smoking status (never, former, current, and not specified). Other factors (height, weight, waist circumference, waist-to-hip ratio, education, physical activity, self-reported diabetes, and dietary intake of energy, fiber, tea, coffee, red and processed meats, fish, fruits and vegetables) were tested as potential confounders, but were excluded from final models for parsimony, as they did not affect the observed risk estimates (change-in-estimate <10% as never drinkers indicated no alcohol intake at baseline, and no past alcohol intake.
Former drinkers indicated no alcohol intake at baseline, but did have past alcohol intake. Drinkers at recruitment indicated alcohol intake at baseline, but did not have past alcohol intake. Lifetime drinkers were defined as those who indicated alcohol intake at both baseline and prior. All the categories of alcohol exposures assessed are mutually exclusive.
Statistical significance of interactions (p<0.05) was assessed using likelihood ratio tests based on the models with and without the interaction terms. Sensitivity analyses were performed including additional adjustment and/or stratification by hepatitis status, AFP, BARD score, liver function tests, sex, years of follow-up and diabetes.
P-values<0.05 were considered statistically significant. Analyses were performed using Stata version 11 (StataCorp, College Station, Texas) and R software, 
Results
Participants Characteristics and Baseline Circulating Osteopontin Levels.
Baseline characteristics of the study participants (N cases = 100 and N controls = 194) and p values for differences are presented in Table 1 . HCC cases were diagnosed on average 4.8 (±2.9) years after recruitment and baseline blood collection. They were more likely to be men, and compared with controls, they were more likely to be current smokers, to have higher BMI and to have diabetes. They were also more likely to present at recruitment with higher alcohol intake and with chronic HBV or HCV infection.
Baseline AFP levels and markers of liver function are also presented in Table 1 . Figure S2) .
In separate models, we evaluated potential interactions of the association between OPN levels and HCC risk by sex, age at recruitment, baseline and lifetime alcohol consumption and smoking status. We did not observe any statistically significant effect modifications (all P for interaction > 0.05). Additional adjustment for AFP, BARD score, AST/ALT ratio, liver function tests and HBV/HCV status did not alter the findings for OPN (Supplementary Table S2 Table S2 ). However, the associations did not differ significantly by sex or years of follow-up (all P-values for heterogeneity>0.10). Models stratified by viral hepatitis status showed that while circulating OPN levels were significantly associated with higher HCC risk in both HBV/HCV positive and negative subjects, the association was stronger in HBV/HCV positive subjects ( Table S2 ). Finally, the association between OPN levels and HCC risk did not change substantially after excluding participants with AFP levels ≥ 20 or ≥ 10 ng/ml and after exclusion of participants that self-reported type 2 diabetes at baseline (Supplementary Table S2 ).
Diagnostic Performance of OPN for HCC Risk
Receiver operating characteristics (ROC) curves were constructed to evaluate OPN performance as a marker for HCC risk in all participants and among cases diagnosed within two years of follow-up. ROC curves were also used to assess whether 
Discussion
In this study, we observed a statistically significant positive association between plasma OPN levels and risk of first incident HCC. The results were stronger among cases diagnosed during the first years of follow-up, and did not change substantially after excluding hepatitis positive participants, or after adjustment for biomarkers of liver function. Also, among cases diagnosed during the first two years of follow-up, OPN alone or in combination with AFP showed better diagnostic performance of HCC compared to AFP alone.
Most HCC cases are diagnosed at a late stage when curative treatments are not applicable. A recent multi-regional retrospective study showed that survival from first HCC treatment varied significantly by region, with median overall survival of 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China, respectively (P<0.0001), underscoring the need for earlier HCC diagnosis worldwide (23) . Given the rising incidence of this cancer in developed countries, it is critically important to identify those at high risk for HCC and institute effective surveillance strategies for early diagnosis. HCC is a cancer well suited for screening given its occurrence in identifiable high risk populations such as patients with liver cirrhosis or chronic HBV infection status. While surveillance for HCC in patients with cirrhosis is recommended, the uptake of HCC surveillance by the medical community has been poor. Better assessment of an individual's risk of HCC could help clinicians increase adherence to screening programs. Most prediction models for HCC have been developed in high risk groups such as patients with liver cirrhosis or chronic HBV or HCV infection (24-32) and most models included age and levels of transaminases. Only two studies on HCC risk prediction models have been performed on the general population and both of them were performed in large cohorts from Taiwan (33, 34 
In the first Taiwanese population cohort study, transaminase levels were shown to be predictive of HCC development within 10 years independently of known HCV or HBV infection status (33) . In that cohort the average of follow-up for HCC incidence was 8.5 years. In the second Taiwanese population cohort study, family history of HCC and cumulative smoking improved a model based on transaminases alone (34) . All these models, whether they were developed on high risk groups or in general populations, used only a combination of readily available parameters and liver function tests such as liver transaminase or albumin. Our study is the first to include a novel HCC biomarker.
While we also found that liver function tests indicative of liver injury, could predict HCC development in the EPIC cohort independently of HCV or HBV infection status, we showed that a model based on liver function can be moderately improved by the addition of OPN. We have previously identified OPN as an early stage HCC biomarker in patients with liver cirrhosis or chronic hepatitis and showed that OPN is already elevated a year prior to diagnosis (8) . We also reported that OPN and AFP are OPN is a secreted non-collagenous, matrix glycoprotein, implicated in the progression of fibrosis and cancer and an influential factor in the tumor microenvironment (35, 36) . In the liver, OPN has been shown to modulate regeneration, inflammation and fibrosis and more recently, to induce dedifferentiation of hepatocytes (37, 38) . Our group has also shown that OPN is necessary for the survival of CD24 able to adjust for a number of important risk factors, liver function markers, and hepatitis infection status, the presence of possible residual confounding may not be ruled out.
In conclusion, this study has shown that higher pre-diagnostic OPN levels in plasma is associated with higher risk of first incident HCC among Europeans.
Assessment of the risk of HCC development is essential for formulating personalized surveillance or for prevention strategies. We identified simple models using OPN circulating levels, for the identification of patients at high risk of developing HCC and for use as a decision rule for clinical action. Because these models are independent of known risk factor for HCC, they could have utility in assessing individual annual risk of developing HCC in subjects previously thought to be at low or average risk because of unknown risk factors or undiagnosed cirrhosis. Large prospective studies, and studies in other populations, are needed to further optimize the model in relation to time of diagnosis and to evaluate its utility as a decision rule for clinical action.
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